DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1

Decoy Receptor 3 Is a Prognostic Factor in Renal Cell Cancer

(2015) Stephan Macher-Goeppinger et al.   NEOPLASIA

Decoy Receptor 3 Enhances Tumor Progression via Induction of Tumor-Associated Macrophages

(2012) S.-K. Tai et al.   JOURNAL OF IMMUNOLOGY

Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer

(2011) Wan-Wan Lin et al.   BIOCHEMICAL PHARMACOLOGY

Decoy Receptor 3 Attenuates Collagen-induced Arthritis by Modulating T Cell Activation and B Cell Expansion

(2011) CHIA-PI CHENG et al.   JOURNAL OF RHEUMATOLOGY

The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid

(2009) André M. Mueller et al.   JOURNAL OF NEUROIMMUNOLOGY

Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3

(2008) Y.-C. Chang et al.   BLOOD

Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance

(2008) Joseph P. Connor et al.   GYNECOLOGIC ONCOLOGY

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY